METTL3 and prostate carcinoma: Specifically, the silencing of METTL3 conferred by siRNAs or the treatment with the METTL3‐pharmacological inhibitor STM2457 has been shown to significantly alter the transcriptome and splicing patterns regulated by androgens in prostate cancer cells.90